-
-
-
TOSITUMOMAB (Bexxar)
- CD20 receptors.
- conjugated to Iodine-131.
- non-Hodgkin’s lymphoma, all expressing CD20 antigen.
- The administration is done in two steps 7-14 days apart and each step has two components
-
(Adcatris)
Brentuximab vedotin
-
Brentuximab vedotin
(Adcatris)
-
Brentuximab vedotin (Adcatris)
- CD30
- classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
- attached to an antimitotic agent monomethyl auristatin E.
- internalized by endocytosis and selectively targets the tumor cells.
- Chemotherapy-induced peripheral neuropathy
-
-
-
-
-
PANITUMUMAB (Vectibix)
- (IgG2)
- epidermal growth factor receptors EGFR
- colorectal cancer in patients who have not responded well to standard
- EGFR which plays a role in resistance to chemotherapy and radiation.
-
-
-
CENTUXIMAB (Erbitux)
- (IgG1)
- epidermal growth factor receptors (HER1)
- expressed on epithelial tissue as well as on the tumors of the colon, rectum, head and neck.
- suppresses cell growth and decreases in the production of matrix metalloproteinase and vascular endothelial growth factor.
- head, neck and colorectal cancers and in combination with radiation therapy it is indicated for the treatment of squamous cell carcinoma
- not given in combination with radiation to patients who did not exhibit a good response to platinum-based therapy.
-
-
-
BEVACIZUMAB (Avastin)
- (IgG1)
- vascular endothelial growth factor (VEGF)
- VEFG promotes the proliferation of endothelial cells and formation of new blood vessels.
- In combination with a standard chemotherapeutic regimen (5-fuouracil-based) it is used for the treatment of patients with malignant colon or rectal cancer.
-
-
-
IPILIMUMAB (Yervoy)
- malignant melanoma.
- It binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4).
- CTLA-4 is expressed on the surface of helper and regulatory T cells.
- CTLA-4 binds to CD80 and CD86 (B7) on antigen presenting cells.
- CTLA-4 regulates T cell responses in fighting disease.
- The antibody blocks the function of CTLA-4, resulting in a sustained immune response that attacks the cancer cells.
- The drug causes an increase in the percentage of activated HLA-DR+ T cells and a mean decrease in the percentage of CCR7+ CD45RA+ T cells.
|
|
